← Back to Search

Janus Kinase (JAK) Inhibitor

Delgocitinib for Chronic Hand Dermatitis (DELTA3 Trial)

Phase 3

Waitlist Available

Research Sponsored by LEO Pharma

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from baseline to week 38

Awards & highlights

DELTA3 Trial Summary

This trial is to see if a drug is safe to use in the long term. Subjects will visit the clinic every 4 weeks and have a final phone call on Week 38.

Eligible Conditions

Chronic Hand Dermatitis

DELTA3 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from baseline to week 38

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from baseline to week 38

This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline to week 38 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of treatment-emergent adverse events from baseline up to Week 38

Secondary outcome measures

HECSI score at each scheduled visit from baseline up to Week 36

HECSI-75 at each scheduled visit from baseline up to Week 36

HECSI-90 at each scheduled visit from baseline up to Week 36

+2 more

DELTA3 Trial Design

1Treatment groups

Experimental Treatment

Group I: As-needed treatment with delgocitinibExperimental Treatment1 Intervention

Subjects will be treated with delgocitinib cream 20 mg/g twice daily as needed.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Delgocitinib

2021

Completed Phase 3

~1330

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

LEO PharmaLead Sponsor

268 Previous Clinical Trials

187,650 Total Patients Enrolled

Medical ExpertStudy DirectorLEO Pharma

53 Previous Clinical Trials

9,300 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are other researchers saying about Delgocitinib?

"Currently, there are two on-going clinical trials studying Delgocitinib. Of these active investigations, 2 have progressed to Phase 3. While the primary focus of these studies is in Cobourg, Ontario - research locations for this medication extend to 137 different centres."

Answered by AI

Are there any patients you're still looking for to join this trial?

"This research is no longer recruiting patients for participation. The listing was originally published on August 23rd, 2021 but was last edited on October 28th, 2022. If you are looking for other similar studies, there are currently 172 trials seeking participants who have eczema and 2 studies searching for Delgocitinib patients."

Answered by AI

Is it advisable to take Delgocitinib?

"Since this is a Phase 3 trial, there is some efficacy data available as well as multiple rounds of safety data. Therefore, our team at Power has estimated the safety of Delgocitinib to be a 3 on a scale from 1 to 3."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials

2021. "Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04949841.